GMAB logo
NASDAQ · GMABBiotechnologyUpdated Nov 2, 2026

Genmab A/S ROE

Profitability, historical returns, and peer comparisons.

The ROE as of November 2026 (TTM) for Genmab A/S (GMAB) is 13.58%

According to Genmab A/S’s latest financial reports and current stock price. The company's current ROE is 13.58%. This represents a change of 301.51% compared to the average of 3.38% of the last 4 quarters.

Genmab A/S (GMAB) Historical ROE (quarterly & annually)

How has GMAB ROE performed in the past?

The mean historical ROE of Genmab A/S over the last ten years is 18.64%. The current 13.58% ROE has changed -27.17% with respect to the historical average. Over the past ten years (40 quarters), GMAB's ROE was at its highest in in the June 2020 quarter at 18.90%. The ROE was at its lowest in in the September 2017 quarter at -0.10%.

Quarterly (TTM)
Annual

Average

18.64%

Median

17.98%

Minimum

13.32%

Maximum

24.88%

Genmab A/S (GMAB) ROE by Quarter and Year

Discovering the peaks and valleys of Genmab A/S ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 61.39%

Maximum Annual ROE = 24.88%

Minimum Annual Increase = -46.46%

Minimum Annual ROE = 13.32%

Quarterly (TTM)
Annual
YearROEChange
202517.13%-19.88%
202421.38%55.25%
202313.77%-31.11%
202219.98%50.00%
202113.32%-46.46%
202024.88%61.39%
201915.42%-16.06%
201818.37%4.40%
201717.59%-28.46%
201624.59%12.31%

Genmab A/S (GMAB) Average ROE

How has GMAB ROE performed in the past?

The current ROE of Genmab A/S (GMAB) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

17.42%

5-year avg

17.12%

10-year avg

18.64%

Genmab A/S (GMAB) ROE vs. Peers

How is GMAB’s ROE compared to its peers?

Genmab A/S’s ROE is less than Incyte Corporation (7.11%), greater than Legend Biotech Corporation (-8.70%), greater than BioNTech SE (-9.16%), less than Exelixis, Inc. (45.54%), less than ADC Therapeutics S.A. (44.63%), greater than MacroGenics, Inc. (-31.27%), greater than Arcus Biosciences, Inc. (-87.98%), greater than Iovance Biotherapeutics, Inc. (-40.51%), less than Compugen Ltd. (42.57%), greater than ALX Oncology Holdings Inc. (-90.30%),

Build a custom stock screener for Genmab A/S (GMAB) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genmab A/S using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Genmab A/S (GMAB) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Genmab A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Genmab A/S's ROE?

How is the ROE calculated for Genmab A/S (GMAB)?

What is the highest ROE for Genmab A/S (GMAB)?

What is the 3-year average ROE for Genmab A/S (GMAB)?

What is the 5-year average ROE for Genmab A/S (GMAB)?

How does the current ROE for Genmab A/S (GMAB) compare to its historical average?